Dashboard Tools Market News Investing Ideas Pricing
Search 100,000+ stocks...
Sign Up
Log in
Urogen Pharma Ltd banner

Urogen Pharma Ltd
NASDAQ:URGN

Watchlist Manager
Urogen Pharma Ltd Logo
Urogen Pharma Ltd
NASDAQ:URGN
Watchlist
Price: 18.48 USD -0.59% Market Closed
Market Cap: $865m
Write Note Create Alert Ask AI

Profitability Summary

Urogen Pharma Ltd's profitability score is hidden . We take all the information about a company's profitability (such as its margins, capital efficiency, free cash flow generating ability, and more) and consolidate it into one single number - the profitability score. The higher the profitability score, the more profitable the company is.

Sign Up to see
Profitability Score
Sign In
Sign Up

We take all the information about a company's profitability (such as its margins, capital efficiency, free cash flow generating ability, and more) and consolidate it into one single number - the profitability score. The higher the profitability score, the more profitable the company is.

We take all the information about a company's profitability (such as its margins, capital efficiency, free cash flow generating ability, and more) and consolidate it into one single number - the profitability score. The higher the profitability score, the more profitable the company is.

Sign Up to see
Profitability Score
Sign In
Sign Up

Margins

Earnings Waterfall
Urogen Pharma Ltd

Margins Comparison
Urogen Pharma Ltd Competitors

Country Company Market Cap Gross
Margin 		Operating
Margin 		Net
Margin
IL
Urogen Pharma Ltd
NASDAQ:URGN
893.5m USD
Loading...
Loading...
Loading...
FR
Pharnext SCA
OTC:PNEXF
6T USD
Loading...
Loading...
Loading...
US
Abbvie Inc
NYSE:ABBV
368.3B USD
Loading...
Loading...
Loading...
US
Amgen Inc
NASDAQ:AMGN
189.4B USD
Loading...
Loading...
Loading...
US
Gilead Sciences Inc
NASDAQ:GILD
175.3B USD
Loading...
Loading...
Loading...
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
114.7B USD
Loading...
Loading...
Loading...
US
Epizyme Inc
F:EPE
94.1B EUR
Loading...
Loading...
Loading...
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
78.7B USD
Loading...
Loading...
Loading...
AU
CSL Ltd
ASX:CSL
64.8B AUD
Loading...
Loading...
Loading...
US
Seagen Inc
F:SGT
39.3B EUR
Loading...
Loading...
Loading...
NL
argenx SE
XBRU:ARGX
36.7B EUR
Loading...
Loading...
Loading...

Return on Capital

Return on Capital Comparison
Urogen Pharma Ltd Competitors

Country Company Market Cap ROE ROA ROCE ROIC
IL
Urogen Pharma Ltd
NASDAQ:URGN
893.5m USD
Loading...
Loading...
Loading...
Loading...
FR
Pharnext SCA
OTC:PNEXF
6T USD
Loading...
Loading...
Loading...
Loading...
US
Abbvie Inc
NYSE:ABBV
368.3B USD
Loading...
Loading...
Loading...
Loading...
US
Amgen Inc
NASDAQ:AMGN
189.4B USD
Loading...
Loading...
Loading...
Loading...
US
Gilead Sciences Inc
NASDAQ:GILD
175.3B USD
Loading...
Loading...
Loading...
Loading...
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
114.7B USD
Loading...
Loading...
Loading...
Loading...
US
Epizyme Inc
F:EPE
94.1B EUR
Loading...
Loading...
Loading...
Loading...
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
78.7B USD
Loading...
Loading...
Loading...
Loading...
AU
CSL Ltd
ASX:CSL
64.8B AUD
Loading...
Loading...
Loading...
Loading...
US
Seagen Inc
F:SGT
39.3B EUR
Loading...
Loading...
Loading...
Loading...
NL
argenx SE
XBRU:ARGX
36.7B EUR
Loading...
Loading...
Loading...
Loading...

Free Cash Flow

Free Cash Flow Analysis
Urogen Pharma Ltd

Last Value
3-Years Average
FCF Margin
Conversion Rate

See Also

Summary
URGN intrinsic value, competitors valuation, and company profile.
DCF Valuation
URGN stock valuation using Discount Cash Flow valuation method.
Relative Valuation
URGN stock valuation using valuation multiples.
Wall Street Estimates
URGN price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
URGN stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Back to Top
ALPHA SPREAD
Follow us
Join more than 324,800+ value investors using Alpha Spread
Create Free Account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2026 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.

AI Assistant
Get AI-powered insights for any company or topic.
Open AI Assistant
Other Tools
Stock Screener
Discover stocks
Stock Comparison
Smarter decisions through side-by-side analysis
Intrinsic Value Calculator
Discover the true worth of your stocks
DCF Value Calculator
Harness the power of DCF

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett